Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $45.00 at HC Wainwright

Bicara Therapeutics (NASDAQ:BCAX) had its target price upped by HC Wainwright from $42.00 to $45.00 in a report released on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research firms have also commented on BCAX. Rodman & Renshaw initiated coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective on the stock. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Cantor Fitzgerald started coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating for the company. TD Cowen initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. Finally, Morgan Stanley initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price target for the company. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Bicara Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $43.75.

Bicara Therapeutics Stock Up 0.4 %

Shares of Bicara Therapeutics stock opened at $11.65 on Monday. Bicara Therapeutics has a 12-month low of $11.43 and a 12-month high of $28.09. The stock’s 50-day moving average price is $17.08.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($1.14). As a group, equities research analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

Several large investors have recently bought and sold shares of the business. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $31,000. SG Americas Securities LLC bought a new stake in Bicara Therapeutics in the fourth quarter valued at about $147,000. Cinctive Capital Management LP acquired a new position in Bicara Therapeutics in the third quarter valued at about $229,000. Barclays PLC bought a new position in Bicara Therapeutics during the third quarter worth about $255,000. Finally, Jane Street Group LLC acquired a new position in shares of Bicara Therapeutics during the 3rd quarter worth about $309,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.